» Hephaï appoints Armelle Roussac as Commercial Director MyPharma Editions

Posted on Tuesday, June 14, 2022

Hephaï, a French start-up developing a digital education platform based on artificial intelligence, today announced the appointment of Armelle Roussac as commercial director. With this appointment, Hephaï is strengthening its management team to prepare the CE marking of its device, collaborate with partner pharmaceutical laboratories and prepare the launch to the general public by the end of 2022.

In this role, Armelle Roussac will be in charge of preparing the launch to the general public by the end of 2022. She will coordinate the testing phase of the app with healthcare professionals and will also be responsible for developing partnerships with pharmaceutical groups.

“We are delighted to welcome Armelle Roussac to Hephaï, as we have entered a strategic period for our start-up. Following the success of the Zephir guide, it was important for us to be able to quickly provide patients with a free, easy-to-use educational tool to help them use their inhalers correctly and better follow up on their long-term care,” says Dr. Valéry Trosini- Désert with satisfaction. , pulmonologist and co-founder of Hephaï.

Armelle Roussac has recognized expertise in medical devices in France and Europe. Previously, she was the commercial director of Neurolite, a company specializing in medical devices, where she was responsible for sleep medicine for pulmonologists. From 2013 to 2015, Armelle Roussac was Head of Business Development for France and Europe at EyeBrain. She holds a Masters in Neuroscience from the University of Montpellier and a Masters in Business Administration from IAE Montpellier.

“I am proud to be a part of a growing startup that works every day with healthcare professionals and partner pharmaceutical groups to support patients suffering from asthma or COPD. My main task will be to prepare the general public launch of our digital platform, scheduled for the end of the year, with the aim of offering patients a unique tool in France to make good use of their inhalation therapies”, adds Armelle Roussac.

A unique AI-based digital tool for patients suffering from asthma or COPD

The use of inhaled treatments in the management of asthma and COPD is very common. In order to take the treatment correctly, patients must therefore regularly handle their inhaler devices, but errors in use are often numerous and can have a direct negative impact on the administration of the drug, mainly by reducing the benefits of the treatment. For example, it is estimated that 30 to 40% of COPD patients misuse their inhalers1.

In addition, with a reduced consultation time that does not allow either to control the use of prescribed inhalation therapies, or to adequately explain the methods of using inhalers, even in pharmacies, many patients do not know the good practices of using their inhalers. inhaler effectively. Therefore, an educational approach is needed to explain the steps for the proper use of inhalers.

Thanks to the educational application of Hephaï, it becomes possible to characterize the use of the treatment as appropriate or not, and to establish, if necessary, a corrective process and a possible medical alert.

The app, which can be used free of charge by the patient and recommended by the prescribing doctor or pharmacist, will be available on Apple and Android by the end of 2022. It is recognized as a Class 1 medical device.

In France, 41 million inhalers prescribed for respiratory pathologies are sold each year. Worldwide, 299 million people are affected by asthma and COPD, including 9 million in France. The global market for inhalers is expected to reach over US$47 billion by 2026, growing by 5.38% per year during 2021-2026.

1. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J 201 – https://pubmed.ncbi.nlm.nih.gov/28182569/

Source and visual: Hephaï

Leave a Comment